We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EMA: Comparative Studies Not Required for Heparin Biosimilar
EMA: Comparative Studies Not Required for Heparin Biosimilar
The development process for biosimilar heparins no longer requires a comparative clinical trial, according to new guidance from the European Medicines Agency.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor